Tempest Therapeutics (TPST) Non-Current Debt (2017 - 2025)

Tempest Therapeutics has disclosed Non-Current Debt across 9 years of filings, most recently posting $4.2 million for Q1 2025.

• In Q1 2025, Non-Current Debt fell 60.38% year-over-year to $4.2 million; the TTM figure through Mar 2025 stood at $4.2 million (down 60.38% YoY), while the FY2024 annual figure was $6.4 million, up 2.17% from the prior year.
• Non-Current Debt came in at $4.2 million for Q1 2025 at Tempest Therapeutics, down from $6.4 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $15.3 million in Q3 2022 to a low of $4.2 million in Q1 2025.
• Average Non-Current Debt over 5 years is $11.4 million, with a median of $10.6 million recorded in 2024.
• Year-over-year, Non-Current Debt soared 13599.09% in 2021 and plunged 60.38% in 2025.
• Over 5 years, Non-Current Debt stood at $15.1 million in 2021, then slumped by 31.18% to $10.4 million in 2022, then sank by 39.6% to $6.3 million in 2023, then grew by 2.17% to $6.4 million in 2024, then slumped by 34.38% to $4.2 million in 2025.
• Per Business Quant data, the three most recent Non-Current Debt figures were $4.2 million in Q1 2025, $6.4 million in Q4 2024, and $8.5 million in Q3 2024.